Tailor-made therapy for cancer based on tumor angiogenesis and hypoxia
| Project/Area Number |
21591772
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
MORI Akira 京都大学, 医学研究科, 非常勤講師 (60324646)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HATA Koichiro 京都大学, 医学研究科, 助教 (90523118)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 腫瘍血管新生 / 低酸素 / 分子標的治療 / 膵癌 / 肝細胞癌 / 肝移植 / 癌 / 血管新生 / KLF5 / HIF-1α / HIF-1 |
|---|
| Research Abstract |
Kruppel-like factor 5(KLF5) is a transcription factor involved in cell transformation, proliferation, and carcinogenesis that can be up-regulated by RAS mutations. However, controversy persists as to whether it functions as a tumor suppressor or as an oncogene. The overexpression of KLF5 in human pancreatic cancer cells is not mediated by KRAS/Raf/MAPK/Erk signaling, but involves the IL-1beta/IL-1R system, p38, and the transcription factor HIF-1alpha. KLF5 is a promising candidate of target molecule in pancreatic cancer therapy. We are now investigating the clinical significance of KLF5 in pancreatic cancer patients.
|
Report
(4 results)
Research Products
(5 results)
